75,000 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Purchased by Pinion Investment Advisors LLC

Pinion Investment Advisors LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 75,000 shares of the biotechnology company’s stock, valued at approximately $1,410,000.

Several other large investors have also recently modified their holdings of the stock. R Squared Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth approximately $38,000. Van ECK Associates Corp increased its stake in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 788 shares during the period. KBC Group NV grew its holdings in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 1,644 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Arrowhead Pharmaceuticals in the third quarter worth about $149,000. Institutional investors own 62.61% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ARWR shares. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley reiterated a “buy” rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Citigroup lowered their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $41.44.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,850 shares of the company’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. Following the completion of the transaction, the director now owns 36,740 shares in the company, valued at approximately $734,800. This represents a 7.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Christopher Richard Anzalone sold 26,712 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $21.24, for a total value of $567,362.88. Following the sale, the chief executive officer now owns 3,688,335 shares in the company, valued at $78,340,235.40. This trade represents a 0.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 147,432 shares of company stock valued at $2,957,986 in the last quarter. 4.30% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $17.71 on Tuesday. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $36.72. The company’s 50 day moving average is $19.56 and its 200 day moving average is $20.67. The company has a market cap of $2.23 billion, a PE ratio of -3.43 and a beta of 0.95.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). On average, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.